Abstract
As emerging cell therapies move towards the commercialization phase, focus has been placed on establishing scalable and reproducible manufacturing processes and incorporating innovations to streamline cell therapy manufacturing. This article will discuss how strategic partnering between biotech and pharma companies can facilitate the challenging transition of moving therapies through the commercialization pipeline.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
